Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers
详细信息 查看全文
- 作者：Sharon L. Walsha ; b ; c ; d ; e ; sharon.walsh@uky.edu" class="auth_mail" title="E-mail the corresponding author ; Paul A. Nuzzoa ; b ; paul.nuzzo@uky.edu" class="auth_mail" title="E-mail the corresponding author ; Shanna Babalonisa ; b ; shanna.babalonis@uky.edu" class="auth_mail" title="E-mail the corresponding author ; Victoria Casseltona ; victoria.casselton@uky.edu" class="auth_mail" title="E-mail the corresponding author ; Michelle R. Lofwalla ; b ; c ; michelle.lofwall@uky.edu" class="auth_mail" title="E-mail the corresponding author
- 关键词：Opioid ; Mu agonist ; Opioid withdrawal ; Abuse ; Buprenorphine ; Misuse
- 刊名：Drug and Alcohol Dependence
- 出版年：2016
- 出版时间：1 May 2016
- 年：2016
- 卷：162
- 期：Complete
- 页码：190-198
- 全文大小：717 K
文摘
- •
Inpatient study examined persons dependent on short-acting opioids.
- •
Intranasal (IN) buprenorphine/naloxone (BUP/NX) precipitated opioid withdrawal.
- •
IN naloxone slowed the onset of buprenorphine’s opioid agonist effects.
- •
Buprenorphine was self-administered more than BUP/NX.
- •
IN BUP/NX has lower abuse potential and reinforcing efficacy than buprenorphine.